Skip to main content

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

Lyell Immunopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in its T cell product candidates targeting solid tumors.

ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.

Under the terms of the agreement, Lyell Immunopharma obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is eligible to receive platform licensing fees, clinical milestone payments and sales-based payments.

“At MaxCyte, our goal is to maximize the potential of cells to improve patients’ lives, and it is through collaborations such as this that we can achieve success,” said Doug Doerfler, President and CEO of MaxCyte. “We look forward to supporting Lyell Immunopharma in its development of solid tumor treatments for patients with unmet needs.”

MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Each of MaxCyte’s strategic partnerships generates pre-commercial milestone revenue and the vast majority include sales-based payments.

About MaxCyte 
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

MaxCyte Contacts: 

US IR Adviser 
Gilmartin Group 
David Deuchler, CFA 
+1 415-937-5400 
ir@maxcyte.com

US Media Relations 
Spectrum Seismic Collaborative 
Valerie Enes 
+1 408-497-8568 
valerie@spectrumscience.com 

Nominated Adviser and Joint Corporate Broker 
Panmure Gordon 
Emma Earl / Freddy Crossley 
Corporate Broking 
Rupert Dearden 
+44 (0)20 7886 2500 

UK IR Adviser 
Consilium Strategic Communications 
Mary-Jane Elliott 
Chris Welsh 
+44 (0)203 709 5700 
maxcyte@consilium-comms.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.